The medical treatment of inflammatory breast cancer

被引：35

作者：

Dawood, Shaheenah ^{[2
]}

Ueno, Naoto T. ^{[1
,3
]}

Cristofanilli, Massimo ^{[1
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, Breast Med Oncol Dept,Unit 1354, Morgan Welch Inflammatory Breast Canc Res & Clin, Houston, TX 77030 USA

[2] Dubai Hosp, Dept Med Oncol, Dubai, U Arab Emirates

[3] Univ Texas Houston, MD Anderson Canc Ctr, Breast Canc Res Lab, Dept Stem Cell Translat & Cellular Therapy, Houston, TX 77030 USA

来源：

SEMINARS IN ONCOLOGY | 2008年 / 35卷 / 01期

关键词：

D O I：

10.1053/j.seminoncol.2007.11.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The multidisciplinary management of inflammatory breast cancer (IBC) includes neoadjuvant systemic chemotherapy, surgery, radiotherapy, and, in hormone receptor-positive disease, hormonal therapy. The use of induction chemotherapy with anthracyclines and taxanes somewhat improved the prognosis and local control of patients with IBC compared to local modalities alone. Improved understanding of the biological features of the disease has allowed for the development of targeted therapies (eg, trastuzumab and lapatinib) that are changing the outcome of this aggressive disease.

引用

页码：64 / 71

页数：8

共 74 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2]

ANGULOGONZALEZ AM, 2004, CLIN CANCER RES, V10, P6215

[3]

[Anonymous], AAJCC CANC STAGING M

[4]

ATKINS HL, 1961, AMER J ROENTGENOL RA, V85, P860

[5]

Baldini Editta, 2004, Clin Breast Cancer, V5, P358, DOI 10.3816/CBC.2004.n.042

[6]

THERAPY FOR INFLAMMATORY BREAST-CANCER - IMPACT OF DOXORUBICIN-BASED THERAPY [J].

BAUER, RL ;

BUSCH, E ;

LEVINE, E ;

EDGE, SB .

ANNALS OF SURGICAL ONCOLOGY, 1995, 2 (04) :288-294

[7]

BLUMENSCHEIN GR, 1976, BREAST, V2, P16

[8]

INFLAMMATORY CANCER OF THE BREAST - ANALYSIS OF 114 CASES [J].

BOZZETTI, F ;

SACCOZZI, R ;

DELENA, M ;

SALVADORI, B .

JOURNAL OF SURGICAL ONCOLOGY, 1981, 18 (04) :355-361

[9]

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[10]

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study [J].

Burstein, HJ ;

Harris, LN ;

Gelman, R ;

Lester, SC ;

Nunes, RA ;

Kaelin, CM ;

Parker, LM ;

Ellisen, LW ;

Kuter, I ;

Gadd, MA ;

Christian, RL ;

Kennedy, PR ;

Borges, VF ;

Bunnell, CA ;

Younger, J ;

Smith, BL ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :46-53

← 1 2 3 4 5 6 7 8 →